Evidence map›Paper›PMID 25944974›Full record

ArticleDisease markers2015

The relationship between clinical feature, complex immunophenotype, chromosome karyotype, and outcome of patients with acute myeloid leukemia in China.

Bingjie Ding, Lanlan Zhou, Xuejie Jiang, Xiaodong Li, Qingxiu Zhong, Zhixiang Wang, Zhengshan Yi, Zhongxin Zheng, Changxin Yin, Rui Cao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bingjie DingHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Lanlan ZhouHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xuejie JiangHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xiaodong LiHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Qingxiu ZhongHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; Hematology Department, Kanghua Hospital, Dongguan 523080, China.
Zhixiang WangHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhengshan YiHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhongxin ZhengHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Changxin YinHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Rui CaoHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Libin LiaoHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Fanyi MengHematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; Hematology Department, Kanghua Hospital, Dongguan 523080, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mixed phenotype acute leukemia (MPAL) is a complex entity expressing both lymphoid and myeloid immunophenotyping. In the present study, 47 MPAL, 60 lymphoid antigen-positive acute myeloid leukemia (Ly(+)AML), and 90 acute myeloid leukemia with common myeloid immunophenotype (Ly(-)AML) patients were investigated. We found that, in MPAL patients, there were high proportions of blast cells in bone marrow and incidence of hepatosplenomegaly, lymphadenopathy, and Philadelphia chromosome. The overall survival (OS) and relapse-free survival (RFS) in MPAL patients were significantly shorter than those in Ly(+)AML and Ly(-)AML. With regard to the patients with normal karyotype only, the OS and RFS of MPAL were significantly lower than those of the Ly(+)AML and Ly(-)AML; but there were no significant differences in OS and RFS among the patients with complex karyotype. The OS rates of 3 groups with complex karyotype were lower than those of patients with normal karyotype. In Cox multivariate analysis, complex karyotype was an independent pejorative factor for both OS and RFS. Therefore, MPAL is confirmed to be a poor-risk disease while Ly(+)AML does not impact prognosis. Complex karyotype is an unfavorable prognosis factor in AML patients with different immunophenotype. Mixed immunophenotype and complex karyotype increase the adverse risk when they coexist.

Indexed as

KaryotypeAdolescentAdultAgedAged, 80 and overAntigens, CDAntigens, LyBone Marrow CellsChildChild, PreschoolChinaFemaleHumansImmunophenotypingLeukemia, Biphenotypic, AcuteMaleAntigens, CDAntigens, Ly

Identifiers

PMID25944974
PMCPMC4405022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.